Objective: The prognosis of patients with peripheral arterial disease (PAD) is characterized by an exceptionally high risk for myocardial infarction, ischemic stroke, and death; however, studies in search of new prognostic biomarkers in PAD are scarce. Even though low levels of high-density lipoprotein cholesterol (HDL-C) have been associated with higher risk of cardiovascular (CV) complications and death in different atherosclerotic diseases, recent epidemiologic studies have challenged its prognostic utility. The aim of this study was to test the predictive value of HDL-C as a risk factor for ischemic events or death in symptomatic PAD patients.
The prognosis of patients with peripheral arterial disease (PAD), considered atherosclerotic occlusive disease of the lower extremities, is characterized by an exceptionally high risk for myocardial infarction, ischemic stroke, and death. [1] [2] [3] This is true for all PAD stages, besides the probability of deterioration of leg symptoms, 4 although 1-year mortality, which can be as high as 25% in patients with critical limb ischemia (CLI), might rise to 45% in subjects undergoing amputation. 5 The current challenge remains in the identification of markers able to discover patients who are at great risk for cardiovascular (CV) events before clinical syndromes develop as traditional atherosclerosis factors, such as diabetes mellitus, cigarette smoking, advanced age, hyperlipidemia, and hypertension, are poor predictors of ischemic events and mortality in lower limb arterial disease. 6 Disorders of lipoprotein metabolism, in particular plasma triglycerides and reduced high-density lipoprotein cholesterol (HDL-C) levels, are established risk factors for CV diseases. 7, 8 Numerous studies have shown that HDL-C levels are inversely associated with the development of atherosclerosis in patients free of CV disease 9 and with the risk of future events in the setting of secondary prevention. 7, 10 This has recently been challenged by clinical trials showing that the inverse relationship of HDL-C levels with CV mortality was weaker in patients with established coronary artery disease (CAD) than in those without CAD. 11, 12 The role of HDL-C as a prognostic marker of worse outcome in PAD is still unclear as few reports address this issue, 9, 13 and in some, the definition of PAD might include abdominal aortic aneurysm and lower limb atherosclerosis subjects in the same group. 14 It has been suggested that the type of vascular disease and the extent of atherosclerosis can influence the relations between lipids and the risk of recurrent events. 15 Therefore, we decided to evaluate, first, the association between HDL-C levels and PAD severity, restricted to patients with atherosclerotic occlusive disease of the lower extremities, and second, the utility of HDL-C as a prognostic marker for the prediction of major adverse CV events (MACEs) and mortality in PAD. 
METHODS
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A thorough medical history was recorded for all patients, including details of previous myocardial infarction, nonischemic cardiomyopathy, arterial hypertension, cerebrovascular disease, smoking status, diabetes mellitus, body mass index (BMI), and medication. Patients were considered smokers (at least one cigarette daily on average during the past year), never smokers, and former smokers (no cigarette consumption in the past year). Diabetes was defined by history of diabetes mellitus or the use of antidiabetic drugs. Hypertension was defined by any history of hypertension or the use of antihypertensive drugs.
Follow-up. Patients were followed up for a mean period of 2.7 years (SD, 2.01 years) at the outpatient service of the Department of Vascular Surgery every 3 or 6 months, depending on the severity of PAD. At recruitment, patients were tested for biochemical parameters and underwent physical examination and ABI assessment. No patient was lost to the follow-up. For outcome evaluation of PAD patients, CV events and death were recorded at the exact date of the event.
MACEs were defined, including amputation, ischemic coronary disease, cerebrovascular disease, and all-cause mortality as a composite end point.
The study was approved by the Institutional Review Board of the Complejo Hospitalario de Navarra, according to the standards of the Declaration of Helsinki on medical research, and written informed consent was obtained from all patients who were enrolled in this study.
Laboratory analysis. Serum total cholesterol, HDL-C, triglycerides, and glucose were measured in fasting blood samples by standard laboratory techniques. Low-density lipoprotein (LDL) cholesterol was estimated using the Friedewald equation.
Statistical analysis. Continuous variables are presented as mean and SD. Categorical variables are presented as percentages. HDL-C levels were categorized in two groups based on the consensus for metabolic syndrome 17 :
reduced HDL-C for <40 mg/dL in men and <50 mg/dL in women; and normal HDL-C for levels above those cutoffs.
Logistic regression models were used to assess the relationship between HDL-C and PAD severity after adjusting for relevant covariates ( 
RESULTS
Baseline characteristics. PAD patients were divided into two subgroups according to their HDL-C levels as reduced HDL-C (n ¼ 135) and normal HDL-C (n ¼ 119) based on the consensus for metabolic syndrome. 17 As shown in Table I , patients belonging to the reduced HDL-C group were more often diabetic, presented with a lower ABI (P < .001), and had higher arterial stiffness that was recorded as percentage of patients with noncompressible arteries (P ¼ .006). Moreover, former histories of chronic kidney disease, cardiomyopathy, and cerebral ischemia were also more frequent in these individuals. PAD patients were under treatment as recommended by current guidelines, showing a higher number of subjects receiving anticoagulants and beta-blockers among those with reduced HDL-C levels. No differences in antihypertensive treatment or statins were reported.
Reduced HDL-C levels are associated with disease severity. To address whether reduced HDL-C levels were independently associated with disease severity, PAD patients were grouped according to the Fontaine classification into intermittent claudication (n ¼ 139) and CLI (n ¼ 115; Supplementary Table I, online only), and binary regression analysis was performed. There was a univariate association between HDL-C levels and PAD severity (OR, 0.012; 95% CI, 0.07-0.21) that remained unchanged after adjustment by age and sex (OR, 0.11; 95% CI, 0.06-0.21) as well as for other CV risk factors (OR, 0.09; 95% CI, 0.03-0.24), suggesting an association between low levels of HDL-C and PAD severity.
Reduced HDL-C levels are associated with increased mortality and MACE. In this study, CV events and death were recorded during a mean follow-up of 2.7 6 2.01 years to address whether mortality or MACE (composite end point including amputation, ischemic coronary disease, cerebrovascular disease, and all-cause mortality) incidence was associated with HDL-C concentration in PAD patients. The number of deaths during the follow-up was 75 (29%). Cox proportional hazards model (Table II) showed that incident mortality was reduced by 65% in PAD patients with normal HDL-C levels in the unadjusted model (HR, 0.35; 95% CI, 0.21-0.58) and after correction by age and sex (HR, 0.34; 95% CI, 0.21-0.57). When other confounding factors were included, the reduction in incident mortality in the normal HDL-C group was 54% (HR, 0.46; 95% CI, 0.21-0.99). To further explore those observations, adjusted Kaplan-Meier estimates for mortality were plotted. shows that mortality was increased in PAD patients with reduced HDL-C after the multivariate correction. Finally, the time to event for MACE incidence (n ¼ 57 [35%]) was determined as a composite end point in patients with no previous history of myocardial infarction and cerebral ischemia (n ¼ 165; Supplementary Table II, online only). Patients with normal levels of HDL-C (Table III) presented with a reduced risk for MACE (70%) compared with the group with low levels (HR, 0.30; 95% CI, 0.17-0.52); this association was also maintained after adjustment for other variables (age-and sex-adjusted HR, 0.29; 95% CI, 0.17-0.51; multivariate adjusted HR, 0.38; 95% CI, 0.16-0.86). Kaplan-Meier analysis was performed to assess whether time to MACE was associated with HDL-C levels. As shown in Fig, B (multivariate adjusted model), subjects with reduced HDL-C levels presented with more events than the normal HDL-C group.
DISCUSSION
The current investigation evidences that reduced plasma HDL-C levels were associated with increased risk of MACE and mortality in a cohort of patients with symptomatic PAD, independently of other known CV risk factors, thus representing a valuable predictor of CV events.
The prognosis of patients with lower extremity PAD is characterized by increased risk of ischemic events due to concomitant coronary artery and cerebrovascular disease, besides the probability of deterioration of leg symptoms. 15 It is not surprising that PAD patients have the lowest quality of life of all symptomatic CV disease manifestations. 3, 4 Numerous prospective studies have confirmed HDL-C as a strong, consistent, and independent predictor of the incidence of CV events (myocardial infarction, ischemic stroke) for different manifestations of atherosclerosis in both primary and secondary prevention, 19, 20 even in those patients with high statin treatment and reduced LDL levels. 21 Based on those studies, HDL-C has been included in diverse CV risk equations and algorithms and has been recognized as a critical component in risk prediction in European and American guidelines. 22 Nevertheless, recent translational studies suggest that the inverse association between CV complications and HDL-C levels might not be as strong as anticipated, at least in CAD. Likewise, different authors have reported that low HDL-C levels are poor predictors of CV events in patients with established (stable and unstable) CAD, whereas it was of utility in patients without CAD. 11, 12 The question remains whether this simple test can be useful to evaluate CV risk in other pathologic processes, such as PAD, because the type of vascular disease and the extent of atherosclerosis can influence the relationship between lipids and the risk of recurrent events. 15 HDL-C concentration has been inversely associated with PAD development in primary prevention 9 as well as in recently diagnosed PAD patients. 13 However, the prognostic value of HDL-C in secondary prevention of PAD has not been properly assessed. Hajer et al showed that higher levels of HDL-C were associated with reduced risk for development of vascular events in patients with aneurysm of the abdominal aorta or with symptomatic and documented obstruction of distal arteries of the leg, 14 which is not a pure PAD population. This study includes patients with symptomatic lower limb atherosclerosis, showing an inverse association between HDL-C and PAD severity and mortality before and after adjustment for other variables. The association remained significant in exploring the incidence of MACE in a subgroup of patients with no previous history of myocardial infarction and cerebral ischemia. The relationship between HDL-C and CV events in patients treated with statins or with very low LDL levels is somehow controversial 7 ; thus, in this study, we considered statin treatment and LDL levels important variables for the multivariate analysis. Indeed, in some large clinical trials with statins but not in all, on-treatment HDL-C was predictive of incident CV events. 23, 24 In the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, the ability of HDL-C to predict incident events in patients treated with high-dose statin was weak, 25 although in a large meta-analysis of eight statin trials, baseline HDL-C concentrations were strongly predictive of subsequent CV events among statin-treated patients. 21 In our population, the percentage of individuals receiving statin treatment was similar (z65%) in both HDL-C groups and when included in the multivariate analysis did not modify the association between the risk for MACE or mortality and HDL-C. In controlling for LDL levels, which were reduced in the low HDL-C group, the independent association between the risk for MACE and death was also maintained, indicating that there might be a residual risk for CV events and mortality in patients with reduced HDL-C levels even when LDL levels are at target levels.
Raising of HDL-C levels has been proposed as a therapeutic alternative for those patients with high CV risk, 26 although the scant clinical trials have been somehow disappointing. 26 Patients receiving statin therapy did not benefit from additional HDL-C and LDL cholesterol modification by the use of niacin, as no net benefit for CV risk reduction and some increase in the risk of side effects were reported. 27 Moreover, two cholesteryl ester transfer protein inhibitors (torcetrapib and dalcetrapib) have failed the purpose of reducing CV risk, 28, 29 although it might be premature to speculate whether this class of drugs will show a benefit, harm, or futility until phase 3 randomized clinical trials with anacetrapib and evacetrapib are finished. 26 A novel approach focuses on promoting the reverse cholesterol transport pathway rather than on raising HDL-C. Likewise, infusions of apolipoprotein A-I, or HDL-like particles, showed encouraging data in some but not in all phase 2 studies using coronary intravascular ultrasound. [30] [31] [32] Interestingly, in patients with PAD, infusion of reconstituted HDL resulted in decreased lipid content of excised femoral plaque as well as decreased inflammatory markers compared with saline. 33 There is substantial enthusiasm for this approach as a promising new therapy, although significant work remains to be done.
Limitations of the study. The sample size could be regarded as small, but the high number of events provides the statistical power required to support our conclusions. The relatively short follow-up period (2.7 years) is useful to estimate early rather than long-term MACE and mortality in PAD patients, but it is still reasonable to characterize important hard points, although the role of HDL-C as a prognosis marker of CV events should be evaluated in longer term studies. This is a prospective study showing an association between low HDL-C levels and worse outcome; however, no causal relationship between CV events and low HDL-C levels can be inferred from this work. This cohort contains few women, although the study is reflective of the clinical practice in our medium as patients were not selected by gender but enrolled at the time of clinical evaluation if they fulfilled our selection criteria. Gender differences in the incidence and prevalence of PAD are less clear than for other CV diseases. Some epidemiologic studies show a similar prevalence of PAD in men and women, 34 whereas others suggest that the prevalence of PAD, symptomatic or asymptomatic, is slightly greater in men than in women, particularly in the younger age groups. the low number of enrolled women, even though no significant interaction between HDL-C and gender was observed. Association analysis between baseline HDL-C measurement and outcome in PAD has not taken into account potential variations in HDL-C during the followup period or changes in lipid-lowering treatment. In this study, we have not considered HDL-related parameters such as concentrations of apolipoprotein A-I and HDL subfractions, which some authors consider better risk predictors than HDL-C. Moreover, future studies should also assess whether reduced HDL-C concentration in PAD is accompanied by changes in the functional properties.
CONCLUSIONS
This study confirms that HDL-C may represent an important independent prognostic biomarker of CV disease in patients with symptomatic PAD. These findings highlight the usefulness of this simple test for early identification of PAD patients at high risk of mortality and MACE.
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